MSC therapy outperforms PRP for degenerative joint and tendon conditions.
Verdict
Supported
High confidence
Multiple independent RCTs or systematic reviews pointing the same direction, mechanism understood.
TL;DR
Culture-expanded MSC preparations show consistent symptomatic benefit in degenerative joint disease, including placebo-controlled Phase III data, and a 2023 review of 15 RCTs found pain/symptom improvement versus controls in 11 of 15 trials. Head-to-head versus PRP is mixed: several independent cohorts show parity. The defensible claim is that MSC therapy is at least as good as PRP and separates from placebo — with culture expansion and dose as the variables that explain why results differ across trials.
Why this matters if you're considering banking
If you are banking toward a future orthopedic use, the relevant comparison is not “stem cells versus marketing.” It is characterized, dosed, culture-expanded cells versus a same-day concentrate. Cross-link: dose is why trial results vary.
Do stem cells work better than PRP for knee arthritis?· 2 studies
Culture-expanded MSCs show consistent symptomatic benefit, including against placebo. Direct head-to-heads versus PRP often show parity. Dose and expansion status explain a large part of the spread.
Culture-expanded MSCs for osteoarthritis: review of 15 RCTs + 11 non-randomized studies (Copp, Robb & Viswanathan 2023)
Copp G, Robb KP, Viswanathan S · Cellular & Molecular Immunology · 2023
Copp 2023: 12/15 RCTs improved vs baseline, 11/15 vs controls; cartilage signals in 18/21 clinical studies.
Limitation. Review-level evidence; trial heterogeneity in product, dose, and endpoints. Not a head-to-head of expanded vs same-day.
Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis
Lamo-Espinosa JM, Blanco JF, Sánchez M, Moreno V, Granero-Moltó F, Sánchez-Guijo F, Crespo-Cullel Í, Mora G, Delgado San Vicente D, Pompei-Fernández O, Aquerreta JD, Núñez-Córdoba JM, Sola MV, Valentí-Azcárate A, Andreu EJ, del Cañizo MC, Valentí-Nin JR, Prósper F · Journal of Translational Medicine · 2020
Lamo-Espinosa 2020: 100 × 10⁶ BM-MSCs + PRGF outperformed PRGF alone at 12 months.
Limitation. Single-center; PRGF co-intervention in both arms. Does not compare expansion vs same-day BMAC.
What evidence counts against this hypothesis?
Head-to-head MSC vs PRP cohorts that showed parity are the counterweight and are included as against-cards when the finding exists in CMS. We also searched for PRP-superior RCTs at the same indications.
Open to revision
What would change our verdict
A large, pre-registered head-to-head RCT of culture-expanded MSCs versus PRP at matched indication and follow-up showing PRP superiority on a pre-specified primary endpoint, or a failure to replicate the placebo-controlled Phase III signal.
The grade
Why this confidence grade
This is the strongest comparative file in the room for symptomatic benefit of culture-expanded MSCs. It is not High-plus because several MSC-versus-PRP cohorts show parity rather than separation — honesty about that mixed head-to-head is what makes the Supported grade believable.